{"id":866879,"date":"2025-07-07T09:04:36","date_gmt":"2025-07-07T13:04:36","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-antibodies-appoints-industry-veteran-jon-lieber-to-board-of-directors\/"},"modified":"2025-07-07T09:04:36","modified_gmt":"2025-07-07T13:04:36","slug":"immunoprecise-antibodies-appoints-industry-veteran-jon-lieber-to-board-of-directors","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-antibodies-appoints-industry-veteran-jon-lieber-to-board-of-directors\/","title":{"rendered":"ImmunoPrecise Antibodies Appoints Industry Veteran Jon Lieber to Board of Directors"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>ImmunoPrecise Antibodies Appoints Industry Veteran Jon Lieber to Board of Directors<\/b><\/p>\n<p>AUSTIN, Texas&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (\u201cIPA\u201d or the \u201cCompany\u201d), an AI-powered biotherapeutics company, today announced the appointment of Jon Lieber to its Board of Directors, effective immediately.<\/p>\n<p>\nMr. Lieber brings over 30 years of financial and strategic leadership across the biotechnology and life sciences sectors, with deep expertise in capital markets, investor relations, and corporate development. He currently serves as Chief Financial Officer at Rallybio, a clinical-stage biotechnology company developing therapies for severe and rare diseases. He also brings valuable experience in Nasdaq governance, having served as both a senior executive and board member of publicly traded companies.<\/p>\n<p>\n\u201cWe are pleased to welcome Jon to IPA\u2019s Board of Directors during this transformative period for the Company,\u201d said Dr. Jennifer Bath, CEO of ImmunoPrecise. \u201cJon brings the rare and highly valuable combination of Nasdaq board governance and senior executive experience\u2014critical as we navigate commercialization and strategic growth. His deep understanding of capital markets and proven success guiding innovation-driven companies aligns well with our strategy to expand adoption of our LENSai\u2122 and HYFT\u00ae platforms, and to position IPA at the forefront of AI-powered drug discovery.\u201d<\/p>\n<p>\nPrior to Rallybio, Mr. Lieber was CFO at Applied Genetic Technologies Corporation (AGTC), a publicly traded gene therapy company, where he led all capital-raising efforts and oversaw finance, human resources, investor relations, and IT. He has also held senior leadership roles at Danforth Advisors, Histogenics, Repligen, Xcellerex (acquired by GE Healthcare), and Altus Pharmaceuticals. Earlier in his career, he worked in investment banking at Salomon Brothers \/ Salomon Smith Barney and SG Cowen.<\/p>\n<p>\nMr. Lieber currently serves on the Board of Directors of Salarius Pharmaceuticals, where he is a member of both the Audit Committee and the Nominating and Governance Committee, further underscoring his depth of experience in Nasdaq board governance.<\/p>\n<p>\n\u201cI\u2019m excited to join IPA\u2019s Board at such a pivotal time,\u201d said Mr. Lieber. \u201cThe Company\u2019s ability to integrate in silico discovery with translational biology sets it apart in a rapidly evolving biotherapeutics landscape. I look forward to supporting IPA\u2019s continued momentum and strategic execution.\u201d<\/p>\n<p><b>About ImmunoPrecise Antibodies Ltd.<\/b><\/p>\n<p>\nImmunoPrecise (NASDAQ: IPA) is a global leader in AI-powered biotherapeutic discovery and development. Its proprietary HYFT technology and LENSai\u2122 platform enable first-principles-based drug design, delivering validated therapeutic candidates across modalities and therapeutic areas. IPA partners with 19 of the top 20 pharmaceutical companies and is advancing next-generation biologics through data-driven, human-relevant models.<\/p>\n<p><strong>Forward-Looking Statements<\/strong><\/p>\n<p>\nThis press release contains forward-looking statements within the meaning of applicable United States and Canadian securities laws. Forward-looking statements are often identified by words such as \u201cexpects,\u201d \u201cintends,\u201d \u201cplans,\u201d \u201canticipates,\u201d \u201cbelieves,\u201d or similar expressions, or by statements that certain actions, events, or results \u201cmay,\u201d \u201cwill,\u201d \u201ccould,\u201d or \u201cmight\u201d occur or be achieved. These statements include, but are not limited to, statements regarding the anticipated contributions of Mr. Lieber to the Company\u2019s board and strategic direction, the Company\u2019s growth trajectory, and its ability to execute on scientific, commercial, and capital markets initiatives.<\/p>\n<p>\nForward-looking statements are based on management\u2019s current expectations, assumptions, and projections about future events. Actual results may differ materially from those expressed or implied due to a variety of factors, many of which are beyond the Company\u2019s control. These factors include, but are not limited to, changes in leadership dynamics, evolving business strategies, market conditions, regulatory developments, scientific and technological advancements, and other risks related to the Company\u2019s operations and industry.<\/p>\n<p>\nForward-looking statements involve known and unknown risks, uncertainties, and other factors that could cause actual results, performance, or achievements to differ materially from those expressed or implied herein. Additional information regarding risks and uncertainties is included in the Company\u2019s Annual Report on Form 20-F, as amended, for the year ended April 30, 2024 (available on the Company\u2019s SEDAR+ profile at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sedarplus.ca&amp;esheet=54286588&amp;newsitemid=20250707441033&amp;lan=en-US&amp;anchor=www.sedarplus.ca&amp;index=1&amp;md5=0a874353fc2b2e2284c35371659f008b\">www.sedarplus.ca<\/a> and EDGAR profile at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2Fedgar&amp;esheet=54286588&amp;newsitemid=20250707441033&amp;lan=en-US&amp;anchor=www.sec.gov%2Fedgar&amp;index=2&amp;md5=3e57e72d3efe93ea56928c1879857837\">www.sec.gov\/edgar<\/a>). Should any of these risks materialize actual results could vary significantly from those currently anticipated.<\/p>\n<p>\nReaders are cautioned not to place undue reliance on these forward-looking statements. Except as required by law, the Company undertakes no obligation to update or revise forward-looking statements to reflect subsequent events or circumstances.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250707441033r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20250707441033\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20250707441033\/en\/<\/a><\/span><\/p>\n<p><b>Investor Relations Contact<br \/>\n<\/b><br \/>Louie Toma<br \/>\n<br \/>Managing Director, CORE IR<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:investors@ipatherapeutics.com\">investors@ipatherapeutics.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America Canada Texas<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Software Research Pharmaceutical Data Management Technology Infectious Diseases Artificial Intelligence Health Technology Science Biotechnology Other Technology Health<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20250707441033\/en\/1747961\/3\/IPA_Logo_01-03-2023.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>ImmunoPrecise Antibodies Appoints Industry Veteran Jon Lieber to Board of Directors AUSTIN, Texas&#8211;(BUSINESS WIRE)&#8211; ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (\u201cIPA\u201d or the \u201cCompany\u201d), an AI-powered biotherapeutics company, today announced the appointment of Jon Lieber to its Board of Directors, effective immediately. Mr. Lieber brings over 30 years of financial and strategic leadership across the biotechnology and life sciences sectors, with deep expertise in capital markets, investor relations, and corporate development. He currently serves as Chief Financial Officer at Rallybio, a clinical-stage biotechnology company developing therapies for severe and rare diseases. He also brings valuable experience in Nasdaq governance, having served as both a senior executive and board member of publicly traded companies. \u201cWe are pleased to welcome Jon to IPA\u2019s &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-antibodies-appoints-industry-veteran-jon-lieber-to-board-of-directors\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;ImmunoPrecise Antibodies Appoints Industry Veteran Jon Lieber to Board of Directors&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-866879","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ImmunoPrecise Antibodies Appoints Industry Veteran Jon Lieber to Board of Directors - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-antibodies-appoints-industry-veteran-jon-lieber-to-board-of-directors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ImmunoPrecise Antibodies Appoints Industry Veteran Jon Lieber to Board of Directors - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ImmunoPrecise Antibodies Appoints Industry Veteran Jon Lieber to Board of Directors AUSTIN, Texas&#8211;(BUSINESS WIRE)&#8211; ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (\u201cIPA\u201d or the \u201cCompany\u201d), an AI-powered biotherapeutics company, today announced the appointment of Jon Lieber to its Board of Directors, effective immediately. Mr. Lieber brings over 30 years of financial and strategic leadership across the biotechnology and life sciences sectors, with deep expertise in capital markets, investor relations, and corporate development. He currently serves as Chief Financial Officer at Rallybio, a clinical-stage biotechnology company developing therapies for severe and rare diseases. He also brings valuable experience in Nasdaq governance, having served as both a senior executive and board member of publicly traded companies. \u201cWe are pleased to welcome Jon to IPA\u2019s &hellip; Continue reading &quot;ImmunoPrecise Antibodies Appoints Industry Veteran Jon Lieber to Board of Directors&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-antibodies-appoints-industry-veteran-jon-lieber-to-board-of-directors\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-07T13:04:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250707441033r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecise-antibodies-appoints-industry-veteran-jon-lieber-to-board-of-directors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecise-antibodies-appoints-industry-veteran-jon-lieber-to-board-of-directors\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ImmunoPrecise Antibodies Appoints Industry Veteran Jon Lieber to Board of Directors\",\"datePublished\":\"2025-07-07T13:04:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecise-antibodies-appoints-industry-veteran-jon-lieber-to-board-of-directors\\\/\"},\"wordCount\":766,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecise-antibodies-appoints-industry-veteran-jon-lieber-to-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250707441033r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecise-antibodies-appoints-industry-veteran-jon-lieber-to-board-of-directors\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecise-antibodies-appoints-industry-veteran-jon-lieber-to-board-of-directors\\\/\",\"name\":\"ImmunoPrecise Antibodies Appoints Industry Veteran Jon Lieber to Board of Directors - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecise-antibodies-appoints-industry-veteran-jon-lieber-to-board-of-directors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecise-antibodies-appoints-industry-veteran-jon-lieber-to-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250707441033r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2025-07-07T13:04:36+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecise-antibodies-appoints-industry-veteran-jon-lieber-to-board-of-directors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecise-antibodies-appoints-industry-veteran-jon-lieber-to-board-of-directors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecise-antibodies-appoints-industry-veteran-jon-lieber-to-board-of-directors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250707441033r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250707441033r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecise-antibodies-appoints-industry-veteran-jon-lieber-to-board-of-directors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ImmunoPrecise Antibodies Appoints Industry Veteran Jon Lieber to Board of Directors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ImmunoPrecise Antibodies Appoints Industry Veteran Jon Lieber to Board of Directors - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-antibodies-appoints-industry-veteran-jon-lieber-to-board-of-directors\/","og_locale":"en_US","og_type":"article","og_title":"ImmunoPrecise Antibodies Appoints Industry Veteran Jon Lieber to Board of Directors - Market Newsdesk","og_description":"ImmunoPrecise Antibodies Appoints Industry Veteran Jon Lieber to Board of Directors AUSTIN, Texas&#8211;(BUSINESS WIRE)&#8211; ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (\u201cIPA\u201d or the \u201cCompany\u201d), an AI-powered biotherapeutics company, today announced the appointment of Jon Lieber to its Board of Directors, effective immediately. Mr. Lieber brings over 30 years of financial and strategic leadership across the biotechnology and life sciences sectors, with deep expertise in capital markets, investor relations, and corporate development. He currently serves as Chief Financial Officer at Rallybio, a clinical-stage biotechnology company developing therapies for severe and rare diseases. He also brings valuable experience in Nasdaq governance, having served as both a senior executive and board member of publicly traded companies. \u201cWe are pleased to welcome Jon to IPA\u2019s &hellip; Continue reading \"ImmunoPrecise Antibodies Appoints Industry Veteran Jon Lieber to Board of Directors\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-antibodies-appoints-industry-veteran-jon-lieber-to-board-of-directors\/","og_site_name":"Market Newsdesk","article_published_time":"2025-07-07T13:04:36+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250707441033r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-antibodies-appoints-industry-veteran-jon-lieber-to-board-of-directors\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-antibodies-appoints-industry-veteran-jon-lieber-to-board-of-directors\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ImmunoPrecise Antibodies Appoints Industry Veteran Jon Lieber to Board of Directors","datePublished":"2025-07-07T13:04:36+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-antibodies-appoints-industry-veteran-jon-lieber-to-board-of-directors\/"},"wordCount":766,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-antibodies-appoints-industry-veteran-jon-lieber-to-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250707441033r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-antibodies-appoints-industry-veteran-jon-lieber-to-board-of-directors\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-antibodies-appoints-industry-veteran-jon-lieber-to-board-of-directors\/","name":"ImmunoPrecise Antibodies Appoints Industry Veteran Jon Lieber to Board of Directors - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-antibodies-appoints-industry-veteran-jon-lieber-to-board-of-directors\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-antibodies-appoints-industry-veteran-jon-lieber-to-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250707441033r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2025-07-07T13:04:36+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-antibodies-appoints-industry-veteran-jon-lieber-to-board-of-directors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-antibodies-appoints-industry-veteran-jon-lieber-to-board-of-directors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-antibodies-appoints-industry-veteran-jon-lieber-to-board-of-directors\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250707441033r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250707441033r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-antibodies-appoints-industry-veteran-jon-lieber-to-board-of-directors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ImmunoPrecise Antibodies Appoints Industry Veteran Jon Lieber to Board of Directors"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/866879","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=866879"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/866879\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=866879"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=866879"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=866879"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}